Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH

The Lungenklinik Hemer Deutscher Gemeinschafts-Diakonieverband GmbH is conducting a strong portfolio of studies in neoplasms, centered on non-small cell lung cancer and small cell lung cancer. Research here focuses on testing new treatment combinations, improving outcomes for advanced disease, and refining perioperative and biomarker-guided care.

• Advanced and metastatic NSCLC, including biomarker-defined groups such as EGFR, ALK, KRAS G12C, HER2, and ROS1 variants
• Immunotherapy and combination strategies aimed at improving survival and disease control
• Studies in resectable and unresectable lung cancer to support better treatment planning around surgery and chemoradiation
• Evaluation of newer targeted and antibody-based therapies for previously treated or hard-to-treat lung cancers

Overall, this site contributes to advancing personalized care for lung cancer patients through trials designed to assess treatment effectiveness, safety, and the added value of newer therapeutic approaches.

Beyond oncology, the site also studies chronic respiratory tract diseases such as idiopathic pulmonary fibrosis, progressive fibrosing interstitial lung diseases, and progressive pulmonary fibrosis. These trials aim to better understand lung function decline and explore treatments that may slow disease progression.

• Idiopathic pulmonary fibrosis and related fibrosing lung disorders
• Testing therapies intended to preserve lung function and reduce worsening fibrosis
• Research focused on long-term tolerability and ongoing disease management

This work broadens the site’s research profile by addressing serious non-cancer lung conditions that can greatly affect breathing, daily activity, and quality of life.

Several studies at the site examine analytical, diagnostic, and therapeutic techniques used in thoracic oncology, including biomarker-driven treatment selection and combined-modality approaches. The aim is to improve how clinicians identify the right therapy and measure benefit more precisely.

• Biomarker-guided treatment strategies in NSCLC
• Research on combining radiotherapy with systemic treatment to improve control of locally advanced disease
• Studies evaluating response, survival, and disease-free outcomes to support better treatment decisions

At Lungenklinik Hemer, this research helps connect modern diagnostics with more tailored treatment strategies for patients with complex lung diseases.

The site also includes trials in eosinophilic asthma, reflecting interest in inflammatory airway disease alongside its cancer-focused program. These studies are designed to evaluate whether newer add-on treatments can improve symptom control in patients who remain poorly controlled on standard therapy.

• Eosinophilic asthma with inadequate control on usual inhaled treatment
• Assessment of new biologic approaches to improve asthma management
• Focus on treatment effectiveness and safety in everyday respiratory care

This adds a broader respiratory medicine dimension to the site’s clinical research, supporting patients with both malignant and non-malignant lung conditions.